| Name | Title | Contact Details |
|---|
NBTY is a leading global vertically integrated manufacturer, marketer and distributor of a broad line of high-quality, value-priced nutritional supplements in the United States and throughout the world. Under a number of NBTY and third party brands, the Company offers over 22,000 products, including products marketed by the Company`s Nature`s Bounty® (www.NaturesBounty.com), Vitamin World® (www.VitaminWorld.com), Puritan`s Pride® (www.Puritan.com), Holland and Barrett® (www.HollandAndBarrett.com), Rexall® (www.Rexall.com), Sundown® (www.Sundownnutrition.com), MET-Rx® (www.MetRX.com), WORLDWIDE Sport Nutrition® (www.SportNutrition.com), American Health® (www.AmericanHealthUS.com), GNC (UK)® (www.GNC.co.uk), DeTuinen® (www.DeTuinen.nl), LeNaturiste (www.LeNaturiste.com), SISU® (www.SISU.com), Solgar® (www.Solgar.com) and Ester-C® (www.Ester-C.com) brands.
Headquartered in Louisville, KY, Trilogy Health Services was founded in December 1997 and is dedicated to being the Best Healthcare Company in the Midwest by providing exceptional, comprehensive care to seniors in our living communities. Trilogy has over 100 locations and continues to grow across IN, OH, MI and KY. Join our growing company and experience the Trilogy Difference.
Moran Vista Assisted Living is a Spokane, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.
CancerLinQ, a subsidiary of ASCO, is a mission-driven, non-profit health technology company focused on improving quality of care, advancing biomedical research, and improving health outcomes for all patients with cancer. Backed by ASCO, CancerLinQ`s products and services reflect a deep understanding of the needs of oncologists, cancer centers, and researchers. We are bilingual by design: fluent in both the language of oncology and technology. As a trusted partner to over 100 cancer centers and community oncology practices, CancerLinQ is uniquely positioned to advance cancer care and research.